S&P 500 7,457.69 -1.01% NASDAQ 25,520.24 -1.40% DOW 52,146.42 -0.77% R2K 2,962.22 -0.42% VIX 18.77 +12.19% US 10Y 4.54 -0.61% DXY 100.75 +0.02% GOLD 4,012.70 +0.68% CRUDE 82.49 +4.48% BITCOIN 64,688.39 +1.23%
Next Bullish Trade
Sign in
BMY

Bristol-Myers Squibb Company BMY

$60.74 +0.23 (+0.38%)
Extended · +1.79σ
Mkt cap $118.0B
P/E 17.3
Day $60.47 – $62.29
52wk $53.44 – $62.89
Avg vol
Beta
Div yld
Next earnings

Quick read

Plain English

Bristol-Myers Squibb Company is a healthcare company listed in the US.

BMY last traded at $60.74, up 0.4% on the day; that's in the upper part of its 52-week range ($53.44–$62.89). Right now it's trading above its recent average — momentum is positive, though some of the move may already be in the price.

Earnings reports are the biggest scheduled catalysts to keep an eye on, and after a strong run, watch whether the price can hold its gains on quieter days.

A plain-English snapshot built from the data on this page — not investment advice. Always do your own research.

132-Day Trend Zones

Full chart →
21 EMA +1 ATR +2 ATR −2 ATR
O H L C

Under the hood

On the latest daily bar, momentum sits mid-range (RSI 61), the trend is quiet (ADX 17), and volume is about normal (0.9×). On the business side, revenue is growing 3% year over year and the business keeps about 20 cents of every sales dollar as free cash.

Latest-bar indicator readings behind the grade — display-only, they don't move the letter.

Momentum · RSI
61
0–100 · <30 oversold
Trend strength · ADX
17
>25 = strong trend
Volume vs avg
0.90×
1× = average
Stretch from avg
+1.8 ATR
− below · + above
Zone touches
4
tests of this zone
Suggested hold
3–30
bars (≈ days)
Fundamentals at a glance

Company fundamentals for context — display-only, they don't move the grade.

Revenue growth
+2.6%
year over year
Free-cash-flow margin
20.4%
cash kept per $ of sales
Debt / equity
2.31
lower = less leveraged
P/E ratio
17.3
price ÷ yearly profit

Valuation & accounting

Valuation desk →

Our cash-flow model pegs fair value near $55.95 (fair range $56–$96); today's price sits 11% above that estimate. The model's verdict is “Overvalued” and accounting quality screens as Weak. Model estimates only — do your own due diligence.

Intrinsic (DCF)
$55.95
Fair-value range
$55.95 – $96.49
Margin of safety
-11%
Verdict
Overvalued
Accounting quality Weak
  • ✓ Positive retained earnings
  • ✓ Gross margin 72% (pricing power)
  • ⚠ Debt exceeds cash
  • ⚠ Quick ratio 0.86 (fragile)
  • ⚠ Debt/equity 3.87 (fragile)
  • ⚠ Receivables growing faster than revenue

Price implies ~4% growth (vs trailing rev yoy). Model estimate — do your own due diligence.

Key statistics

All statistics →

BMY is a $118.0 billion company, priced at 17× last year's earnings.

Mkt cap $118.0B
P/E ttm 17.3
Fwd P/E
Beta
Day range $60.47 – $62.29
52w range $53.44 – $62.89
Avg vol
RSI(2) 84.2
ROE
Net mgn
FCF mgn 20.4%
Debt/Eq 2.31
Div yld
Sector Healthcare
Industry Drug Manufacturers - General
Next earn
52-week range · today's price
$53.44$62.89

More on BMY